The hottest thing in cancer drug development just won a $9 billion endorsement – Business Insider
Business Insider |
The hottest thing in cancer drug development just won a $9 billion endorsement
Business Insider Juno is known for its experimental, highly personalized cancer treatments called CAR T-cell therapy, which harnesses the body's immune system to go after certain blood cancers. It's part of a new field of cancer therapies that . In 2017, the FDA … Celgene to buy Juno for $9 billion to boost CAR–T expertise UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodes Celgene to buy Juno Therapeutics for about $9 billion – CNBC.com |
